Showing results (2921-2930 of 3,105) with videos related to

Sort By:
Pageof 311
Drug Safety|June 11, 2026
Assessing the Risk of Adverse Maternal and Infant Outcomes Following Prenatal Modafinil Exposure: A French Nationwide Cohort StudySigal Kaplan, Julie de Nascimento, Andrea Contini
Drug Safety|June 20, 2023
Use of Electronic Health Record Data for Drug Safety Signal Identification: A Scoping ReviewSharon E Davis, Luke Zabotka, Rishi J Desai, et al.
Drug Safety|February 1, 1993
How frequent are notified severe cutaneous adverse reactions to Fansidar?D Stürchler, M L Mittelholzer, L Kerr
Drug Safety|April 10, 2026
Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer's Disease: Timing and Duration of Adverse EventsAnton P Porsteinsson, Sanjeda R Chumki, David Wang, et al.
Drug Safety|February 22, 2026
The Evaluation of Transformer Models for the Detection of Adverse Drug Events: A Benchmark Study Using Dutch Free-Text Documents of Hospitalized PatientsRachel M Murphy, Nishant Mishra, Nicolette F de Keizer, et al.
Drug Safety|December 21, 2016
Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 StudyMarten A Lantinga, Hedwig M A D'Agnolo, Niek F Casteleijn, et al.
Drug Safety|November 10, 2016
Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?Edoardo Mannucci, Matteo Monami
Drug Safety|December 1, 2016
Propensity Score Weighting Compared to Matching in a Study of Dabigatran and WarfarinJohn D Seeger, Katsiaryna Bykov, Dorothee B Bartels, et al.
Drug Safety|December 17, 2016
Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?Rashmi R Shah
Drug Safety|February 28, 2008
A benefit-risk review of systemic haemostatic agents: part 1: in major surgeryIan S Fraser, Robert J Porte, Peter A Kouides, et al.
Pageof 311